LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...
Recipharm has struck a deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K., picking up new capabilities and clients in the process. The Swedish CDMO ...
DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...
"We are proud to be the only global manufacturing site for Flutiform and feel that it will contribute towards our vision of Holmes Chapel as a center of excellence for the manufacture of inhalation ...
LONDON, UK, 18 October 2011 - SkyePharma PLC (LSE: SKP) today announces that the review of the European Marketing Authorisation Application ("MAA") for Flutiform TM will take longer than originally ...
Recipharm, a Swedish drug services firm, will pay $59 million to acquire Sanofi’s inhalation drug business in Holmes Chapel, England. It will get a 125,000-m 2 facility that specializes in metered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback